The Trump Administration Is Shifting Federal Policy on Cannabis and Psychedelics

The Trump administration moved to reclassify medical marijuana from Schedule I to Schedule III and said it will review marijuana scheduling more broadly.

Officials also signaled stronger support for psychedelic research and faster FDA pathways for related treatments.

Cost Plus Drugs and Humana’s CenterWell Pharmacy announced a partnership to develop employer prescription-cost solutions.

Axoft raised $55 million to advance implantable brain-computer interface trials and manufacturing.